Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE-PMR rituximab study in newly diagnosed polymyalgia rheumatica
NL-OMON45885Phase 2Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and prednisone in polymyalgia rheumatica (PMR), sponsored by Sint Maartenskliniek. Primary endpoint: Proportion of patients in complete glucocorticoid-free remission at week 20. Started Feb 2019; status: active, not recruiting.
02
Drugs
rituximabprednisone
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON45885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45885.